NLTX Annual CFF
$161.00 K
-$571.00 K-78.01%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual cash flow from financing activities is $161.00 thousand, with the most recent change of -$571.00 thousand (-78.01%) on December 31, 2022. During the last 3 years, it has fallen by -$82.08 million (-99.80%).NLTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly CFF
-$1000.00
+$293.00 K+99.66%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly cash flow from financing activities is -$1000.00, with the most recent change of +$293.00 thousand (+99.66%) on September 30, 2023. Over the past year, it has increased by +$51.00 thousand (+98.08%).NLTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM CFF
-$343.00 K
+$51.00 K+12.94%
30 September 2023
Summary:
As of February 5, 2025, NLTX TTM cash flow from financing activities is -$343.00 thousand, with the most recent change of +$51.00 thousand (+12.94%) on September 30, 2023. Over the past year, it has dropped by -$593.00 thousand (-237.20%).NLTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -78.0% | +98.1% | -237.2% |
| 3 y3 years | -99.8% | -100.0% | -100.2% |
| 5 y5 years | -61.9% | +95.5% | -100.4% |
NLTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -99.8% | -100.0% | -100.2% |
Neoleukin Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1000.00(-99.7%) | -$343.00 K(-12.9%) |
| June 2023 | - | -$294.00 K(+345.5%) | -$394.00 K(+936.8%) |
| Mar 2023 | - | -$66.00 K(-466.7%) | -$38.00 K(-123.6%) |
| Dec 2022 | $161.00 K(-78.0%) | $18.00 K(-134.6%) | $161.00 K(-35.6%) |
| Sept 2022 | - | -$52.00 K(-183.9%) | $250.00 K(-25.1%) |
| June 2022 | - | $62.00 K(-53.4%) | $334.00 K(-42.7%) |
| Mar 2022 | - | $133.00 K(+24.3%) | $583.00 K(-20.4%) |
| Dec 2021 | $732.00 K(-99.1%) | $107.00 K(+234.4%) | $732.00 K(-61.7%) |
| Sept 2021 | - | $32.00 K(-89.7%) | $1.91 M(-97.4%) |
| June 2021 | - | $311.00 K(+10.3%) | $74.04 M(+0.0%) |
| Mar 2021 | - | $282.00 K(-78.1%) | $74.03 M(-4.0%) |
| Dec 2020 | $77.14 M(-6.2%) | $1.29 M(-98.2%) | $77.14 M(-51.2%) |
| Sept 2020 | - | $72.16 M(>+9900.0%) | $158.05 M(+83.9%) |
| June 2020 | - | $301.00 K(-91.1%) | $85.93 M(+0.4%) |
| Mar 2020 | - | $3.39 M(-95.9%) | $85.63 M(+4.1%) |
| Dec 2019 | $82.24 M(>+9900.0%) | $82.20 M(>+9900.0%) | $82.24 M(>+9900.0%) |
| Sept 2019 | - | $37.00 K(-1950.0%) | $31.00 K(-210.7%) |
| June 2019 | - | -$2000.00(0.0%) | -$28.00 K(-107.6%) |
| Mar 2019 | - | -$2000.00(0.0%) | $369.00 K(-35.3%) |
| Dec 2018 | $570.00 K | -$2000.00(-90.9%) | $570.00 K(-8.9%) |
| Sept 2018 | - | -$22.00 K(-105.6%) | $626.00 K(-3.2%) |
| June 2018 | - | $395.00 K(+98.5%) | $647.00 K(+3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $199.00 K(+268.5%) | $626.00 K(+48.0%) |
| Dec 2017 | $423.00 K(-99.4%) | $54.00 K(-5500.0%) | $423.00 K(+105.3%) |
| Sept 2017 | - | -$1000.00(-100.3%) | $206.00 K(-99.7%) |
| June 2017 | - | $374.00 K(-9450.0%) | $71.48 M(+0.5%) |
| Mar 2017 | - | -$4000.00(-97.5%) | $71.11 M(-0.0%) |
| Dec 2016 | $71.11 M(-23.5%) | -$163.00 K(-100.2%) | $71.11 M(-0.0%) |
| Sept 2016 | - | $71.27 M(>+9900.0%) | $71.13 M(-23.5%) |
| June 2016 | - | $3000.00(>+9900.0%) | $92.93 M(+0.1%) |
| Mar 2016 | - | $0.00(-100.0%) | $92.88 M(-0.1%) |
| Dec 2015 | $92.95 M(+105.3%) | -$148.00 K(-100.2%) | $92.95 M(-0.2%) |
| Sept 2015 | - | $93.08 M(<-9900.0%) | $93.10 M(<-9900.0%) |
| June 2015 | - | -$52.00 K(-172.2%) | -$30.00 K(-91.8%) |
| Mar 2015 | - | $72.00 K(>+9900.0%) | -$368.00 K(-100.8%) |
| Dec 2014 | $45.28 M(+131.2%) | $0.00(-100.0%) | $45.28 M(-3.8%) |
| Sept 2014 | - | -$50.00 K(-87.2%) | $47.09 M(-0.1%) |
| June 2014 | - | -$390.00 K(-100.9%) | $47.13 M(-0.6%) |
| Mar 2014 | - | $45.72 M(+2428.8%) | $47.44 M(+142.2%) |
| Dec 2013 | $19.58 M(>+9900.0%) | $1.81 M(<-9900.0%) | $19.58 M(+10.2%) |
| Sept 2013 | - | -$3300.00(-96.2%) | $17.78 M(-0.0%) |
| June 2013 | - | -$87.90 K(-100.5%) | $17.78 M(-0.5%) |
| Mar 2013 | - | $17.87 M | $17.87 M |
| Dec 2012 | $0.00 | - | - |
FAQ
- What is Neoleukin Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual CFF year-on-year change?
- What is Neoleukin Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly CFF year-on-year change?
- What is Neoleukin Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM CFF year-on-year change?
What is Neoleukin Therapeutics annual cash flow from financing activities?
The current annual CFF of NLTX is $161.00 K
What is the all time high annual CFF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual cash flow from financing activities is $92.95 M
What is Neoleukin Therapeutics annual CFF year-on-year change?
Over the past year, NLTX annual cash flow from financing activities has changed by -$571.00 K (-78.01%)
What is Neoleukin Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NLTX is -$1000.00
What is the all time high quarterly CFF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly cash flow from financing activities is $93.08 M
What is Neoleukin Therapeutics quarterly CFF year-on-year change?
Over the past year, NLTX quarterly cash flow from financing activities has changed by +$51.00 K (+98.08%)
What is Neoleukin Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NLTX is -$343.00 K
What is the all time high TTM CFF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM cash flow from financing activities is $158.05 M
What is Neoleukin Therapeutics TTM CFF year-on-year change?
Over the past year, NLTX TTM cash flow from financing activities has changed by -$593.00 K (-237.20%)